tsla

Analysts Heap Bullish Attention On Array Biopharma Stock

Leerink boosted Array to "outperform" this morning

Managing Editor
Jan 22, 2018 at 10:18 AM
facebook X logo linkedin


Array Biopharma Inc (NASDAQ:ARRY) is up 13.7% to trade at $14.93, and earlier touched a 16-year high of $15.66, after Leerink upgraded the cancer treatment specialist to "outperform" from "market perform," while issuing a price-target hike to $19 from $12. The upgrade comes after the biotech stock reported strong clinical results over the weekend from its BEACON cancer treatment trials, with Leerink adding that the related sales opportunity could be larger than it previously expected. Stifel and Cowen chimed in with price-target hikes of their own, to $20 and $17, respectively.

The burst today has ARRY stock on track for its best session since February, and the drug stock has now added 68% in the last six months. A mid-December bull gap pushed ARRY stock past the formerly resistant $12 level, and the shares have been guided higher by their rising 20-day moving average ever since. 

A short squeeze could push the biotech stock even higher. Short interest decreased by nearly 27% during the last two reporting periods to 15.17 million shares. This still represents a hefty 11% of ARRY'S total available float, and at the equity's average daily trading volume, it would take nearly five sessions to repurchase these pessimistic positions -- plenty of fuel for additional gains.

This skeptical outlook certainly isn't shared by the broader analyst community. Specifically, eight of the nine covering brokerage firms have handed out "strong buy" recommendations. Moreover, the consensus 12-month price target of $17.78 stands as a 19% premium to the stock's current perch.

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.